16 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
Purdue University
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
Purdue University
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
Purdue University
Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.
University Of Queensland
Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance.
Purdue University
Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
Purdue University
Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.
University Of Illinois At Chicago
Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
University Of Illinois At Chicago
Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis based strategy.
University Of Illinois At Chicago
Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease.
Glaxosmithkline
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
Glaxosmithkline
Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.
Glaxosmithkline
Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
Glaxosmithkline